Crystal Genetics is a leading brand that specializes in developing high-quality liquid-biopsy methods for the early detection of multiple cancers. Their revolutionary liquid-biopsy method, Crystalogram, is a noninvasive technique designed for multi-cancer early detection (MCED). Led by Bahram G.

Kermani, Ph. D., the Founder and CEO of Crystal Genetics, the company is at the forefront of genomics, computational biology, and pattern recognition. With an impressive background in various executive and technical positions in renowned companies like Illumina and Guardant Health, Bahram has extensive expertise in this field.

Crystal Genetics is committed to providing innovative solutions in the realm of genomics and biomedical engineering. They have a team of experts, including Mark B. Baudler, Corporate Legal Advisor, and Mark J.

Sutherland, Business Development Advisor, who bring their wealth of experience working with technology and growth companies to Crystal Genetics. With a focus on using next-generation sequencing, gene expression, and bioinformatics, Crystal Genetics is dedicated to advancing the understanding and detection of cancers through their cutting-edge technology